Nano-silncRNA16

Nano-silncRNA16 (also known as GalNAc-silncRNA16) is an experimental RNA interference (RNAi) therapeutic consisting of a small interfering RNA (siRNA) conjugated to a trivalent N-acetylgalactosamine (GalNAc) moiety. Developed by researchers at the University of South China, it is designed to specifically target and silence long non-coding RNA 16 (lncRNA16), a regulatory RNA that is significantly upregulated in non-small cell lung cancer (NSCLC) and contributes to platinum-based chemoresistance. Mechanistically, lncRNA16 acts as a molecular scaffold in the mitochondria, facilitating the interaction between hemoglobin subunit beta (HBB) and NDUFAF5. This interaction inhibits the generation of reactive oxygen species (ROS) and suppresses autophagy, thereby protecting cancer cells from chemotherapy-induced death. By silencing lncRNA16, Nano-silncRNA16 restores ROS production and enhances the sensitivity of NSCLC cells to platinum-based agents. Preclinical studies have demonstrated that the drug effectively inhibits tumor growth and restores chemosensitivity in mouse models without significant systemic toxicity.

Other names

GalNAc-silncRNA16GalNAc-silncRNA-16GalNAc-silncRNA 16